Co-occurring Alterations in the RAS-MAPK Pathway Limit Response to MET Inhibitor Treatment in MET Exon 14 Skipping Mutation-Positive Lung Cancer.

Julia K RotowPhilippe GuiWei WuVictoria M Raymond Richard B LanmanFrederic J KayeNir PeledFerran Fece de la Cruz Brandon A NadresRyan B CorcoranIwei YehBoris C BastianPetr StarostikKimberly NewsomVictor R OlivasAlexander M WolffBrian K ShoichetEric A CollissonCaroline E McCoachD Ross CamidgeJose PachecoLyudmila BazhenovaTianhong LiTrever G BivonaCollin M Blakely

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2019)

Our study provides a genomic landscape of co-occurring alterations in advanced-stage METex14-mutated NSCLC and suggests a potential combination therapy strategy targeting MAPK pathway signaling to enhance clinical outcomes.

Keyphrases

combination therapy
signaling pathway
oxidative stress
tyrosine kinase
small cell lung cancer
pi k akt
wild type
copy number
cancer therapy
gene expression
risk assessment
human health
epidermal growth factor receptor
genome wide
brain metastases